Study examines outcomes of erythropoietin use for heart attack patients undergoing PCI

Links shared publicly online about this topic.

302
total visits

Study examines outcomes of erythropoietin use for heart attack patients undergoing PCI

Intravenous administration of epoetin alfa, a product that stimulates red blood cell production, to patients with heart attack who were undergoing percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), did not provide reduction in the size of the heart muscle involved and was associated with higher rates of adverse cardiovascular events, according to a study in the May 11 issue of JAMA.

View full resource at eurekalert.org

Tags: Heart, Heart Disease, Anemia Medication, Heart Attack, Thrombotic Event, Procrit, Eprex, Epogen